Vitiligo: an update on systemic treatments

Area of Science:

• Dermatology
• Autoimmune Diseases
• Immunology

Background:

• Vitiligo is an autoimmune skin disorder causing depigmented patches with significant psychosocial effects.
• Current vitiligo treatments focus on halting disease progression and repigmentation, primarily using topical agents and phototherapy.
• Systemic therapies are emerging as crucial options for managing vitiligo, either alone or with other treatments.

Purpose of the Study:

• To review the evidence supporting systemic treatments for vitiligo.
• To evaluate the efficacy of various systemic agents in managing vitiligo.
• To provide an overview of emerging systemic treatment options for vitiligo.

Main Methods:

• Literature review of systemic treatments for vitiligo.
• Analysis of evidence for oral mini-pulsed corticosteroid therapy.
• Examination of data on methotrexate, minocycline, ciclosporin, and Janus kinase inhibitors.
• Inclusion of evidence for certain supplements in vitiligo treatment.

Main Results:

• Systemic treatments demonstrate significant impact on vitiligo course.
• Oral mini-pulsed corticosteroids show efficacy in vitiligo management.
• Methotrexate, minocycline, ciclosporin, and JAK inhibitors are viable systemic options.
• Supplements are also being explored for their role in vitiligo treatment.

Conclusions:

• Systemic therapies are increasingly important in vitiligo management.
• Evidence supports the use of various systemic agents as monotherapy or adjunctive treatment.
• Further research into systemic treatments can improve vitiligo patient outcomes.